Search

everythinglearnresearchcommunity

for

Search:↓

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.

A genetic test can identify people at risk of male pattern baldness early, allowing for quicker treatment.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.

AH-001 could be a safer and more effective treatment for hair loss.

Atoh1 expression can create new Merkel cells in the skin.

AUC and APL are distinct conditions needing careful clinical assessment.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Androgen receptor differences may contribute to hair loss in AGA patients.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Mogamulizumab can cause hair loss and skin rashes.

Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.

The humanized AA mouse model is better for testing new alopecia areata treatments.

Alopecia areata is linked to blood cancers, especially in older patients, but not to most solid cancers.

Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Inflammation and immunity play a key role in androgenetic alopecia, with better treatment outcomes in certain immune-positive cases.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.

Genetically repaired stem cells may treat certain genetic diseases, Th17 cells are key in fighting systemic fungal infections, hair loss in AGA is due to progenitor cell loss, and α-synuclein transfer might contribute to Parkinson's disease progression.

Anti-Müllerian hormone is a specific marker for ovarian issues in women with conditions like PCOS.

Endocrine disruptors may cause early hair loss.

Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

Skin RAGE levels are linked to inflammation and cell death.

Severe alopecia areata involves higher levels of certain immune cells, which can be normalized with betamethasone.

People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.